FDA 483 - Alvotech HF - January 19, 2024

This FDA Form 483 document details observations made during an inspection of a pharmaceutical manufacturing facility. The inspection identified four key deficiencies related to the facility's quality system and manufacturing operations.

Observation 1 indicates a failure to establish adequate procedures for the cleaning and maintenance of equipment. This suggests potential issues with preventing cross-contamination or ensuring equipment is fit for purpose.

Observation 2 highlights that the manufacturing process for Drug X was not adequately validated. This is a critical finding as it implies the process may not consistently produce a product meeting its predetermined specifications and quality attributes, potentially impacting product efficacy and safety.

Observation 3 notes the absence of proper controls to prevent contamination of products. This deficiency could lead to microbial, particulate, or chemical contamination, posing significant risks to patient health.

Finally, Observation 4 states that the firm did not maintain proper records of batch production and control. Inadequate record-keeping hinders traceability, investigations into deviations, and overall quality assurance, making it difficult to demonstrate compliance with Good Manufacturing Practices (GMP).

These observations collectively point to significant gaps in the firm's quality management system, potentially impacting product quality, safety, and regulatory compliance. The document does not specify the facility name, inspection dates, or specific regulatory citations, but the observations clearly indicate non-compliance with fundamental GMP requirements.